Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A. Pestana JO, et al. Among authors: vanrenterghem y. Am J Transplant. 2012 Mar;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x. Epub 2012 Feb 2. Am J Transplant. 2012. PMID: 22300431 Free article. Clinical Trial.
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Larsen CP, et al. Among authors: vanrenterghem y. Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd. Transplantation. 2010. PMID: 21076381
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Vanrenterghem Y, et al. Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb. Transplantation. 2011. PMID: 21372756 Clinical Trial.
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S. Charpentier B, et al. Among authors: vanrenterghem y. Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18. Am J Transplant. 2013. PMID: 24103072 Free article. Clinical Trial.
Five-year safety and efficacy of belatacept in renal transplantation.
Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B. Vincenti F, et al. Among authors: vanrenterghem y. J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15. J Am Soc Nephrol. 2010. PMID: 20634298 Free PMC article. Clinical Trial.
An integrated safety profile analysis of belatacept in kidney transplant recipients.
Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. Grinyó J, et al. Among authors: vanrenterghem y. Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95. Transplantation. 2010. PMID: 21088650
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Among authors: vanrenterghem y. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial.
Vanrenterghem Y, van Hooff JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, Pascual J, Ekberg H, Sicilia LS, Boletis JN, Grinyo JM, Rodriguez MA; European Tacrolimus/MMF Renal Transplantation Study Group. Vanrenterghem Y, et al. Am J Transplant. 2005 Jan;5(1):87-95. doi: 10.1111/j.1600-6143.2004.00638.x. Am J Transplant. 2005. PMID: 15636615 Free article. Clinical Trial.
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.
Vitko S, Wlodarczyk Z, Kyllönen L, Czajkowski Z, Margreiter R, Backman L, Perner F, Rigotti P, Jaques B, Abramowicz D, Kessler M, Sanchez-Plumed J, Rostaing L, Rodger RS, Donati D, Vanrenterghem Y. Vitko S, et al. Among authors: vanrenterghem y. Am J Transplant. 2006 Mar;6(3):531-8. doi: 10.1111/j.1600-6143.2005.01193.x. Am J Transplant. 2006. PMID: 16468962 Free article. Clinical Trial.
368 results